Evidence map›Paper›PMID 21791114›Full record

ArticleMolecular cancer2011

ZEB1 limits adenoviral infectability by transcriptionally repressing the coxsackie virus and adenovirus receptor.

Markus D Lacher, Marisa Shiina, Peter Chang, Debora Keller, Maarit I Tiirikainen, W Michael Korn

Open access · goldAbstract readEvaluation Study
In one paragraph

Article in Molecular cancer, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. [Zinc finger E-box-binding homeobox 2 inhibits hepatitis B virus replication and expression].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2016
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

Markus D LacherDepartment of Medicine, Division of Gastroenterology, University of California, San Francisco, CA, USA.
Marisa Shiina
Peter Chang
Debora Keller
Maarit I Tiirikainen
W Michael Korn
University of California, San Francisco · USLineage Cell Therapeutics (United States) · USUniversity of California San Francisco Medical Center · USUniversity of Hawaii Cancer Center

Funding

Translational InformaticsP30CA082103 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Jennifer Leigh Clarke · 1999 to 2026
$209.7M
The Adenovirus Receptor CAR in Epithelial MalignanciesR01CA095701 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KORN, WOLFGANG MICHAEL · 2003 to 2007
$1.3M
Experimentally Validated Mathematical Modeling of Oncolytic Virus InfectionR01CA118545 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KORN, WOLFGANG MICHAEL · 2006 to 2009
$853k
NCI NIH HHS P30 CA82103NCI NIH HHS R01 CA095701NCI NIH HHS R01 CA118545
6 · The paper itself

Abstract

backgroundWe have previously reported that RAS-MEK (Cancer Res. 2003 May 1;63(9):2088-95) and TGF-β (Cancer Res. 2006 Feb 1;66(3):1648-57) signaling negatively regulate coxsackie virus and adenovirus receptor (CAR) cell-surface expression and adenovirus uptake. In the case of TGF-β, down-regulation of CAR occurred in context of epithelial-to-mesenchymal transition (EMT), a process associated with transcriptional repression of E-cadherin by, for instance, the E2 box-binding factors Snail, Slug, SIP1 or ZEB1. While EMT is crucial in embryonic development, it has been proposed to contribute to the formation of invasive and metastatic carcinomas by reducing cell-cell contacts and increasing cell migration.

resultsHere, we show that ZEB1 represses CAR expression in both PANC-1 (pancreatic) and MDA-MB-231 (breast) human cancer cells. We demonstrate that ZEB1 physically associates with at least one of two closely spaced and conserved E2 boxes within the minimal CAR promoter here defined as genomic region -291 to -1 relative to the translational start ATG. In agreement with ZEB1's established role as a negative regulator of the epithelial phenotype, silencing its expression in MDA-MB-231 cells induced a partial Mesenchymal-to-Epithelial Transition (MET) characterized by increased levels of E-cadherin and CAR, and decreased expression of fibronectin. Conversely, knockdown of ZEB1 in PANC-1 cells antagonized both the TGF-β-induced down-regulation of E-cadherin and CAR and the reduction of adenovirus uptake. Interestingly, even though ZEB1 clearly contributes to the TGF-β-induced mesenchymal phenotype of PANC-1 cells, TGF-β did not seem to affect ZEB1's protein levels or subcellular localization. These findings suggest that TGF-β may inhibit CAR expression by regulating factor(s) that cooperate with ZEB1 to repress the CAR promoter, rather than by regulating ZEB1 expression levels. In addition to the negative E2 box-mediated regulation the minimal CAR promoter is positively regulated through conserved ETS and CRE elements.

conclusionsThis report provides evidence that inhibition of ZEB1 may improve adenovirus uptake of cancer cells that have undergone EMT and for which ZEB1 is necessary to maintain the mesenchymal phenotype. Targeting of ZEB1 may reverse some aspects of EMT including the down-regulation of CAR.

Indexed as

AdenoviridaeAdenoviridae InfectionsBase SequenceCell Line, TumorCoxsackie and Adenovirus Receptor-Like Membrane ProteinDown-RegulationEpithelial-Mesenchymal TransitionFemaleGene Expression RegulationGenetic VectorsGene Transfer, HorizontalHomeodomain ProteinsHumansMolecular Sequence DataReceptors, VirusSequence Homology, Nucleic AcidCLMP protein, humanCoxsackie and Adenovirus Receptor-Like Membrane ProteinHomeodomain ProteinsReceptors, VirusTranscription FactorsZEB1 protein, humanZinc Finger E-box-Binding Homeobox 1

Identifiers

PMID21791114
PMCPMC3164624
OpenAlexW2001550248

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.